Boston Scientific Paid $1.5B for 34% of MiRus — With a $3B Acquisition Option Attached. This Is How Corporate Venture Actually Works.

Most corporate venture capital is theater. A $5 million check, a logo on a cap table, a press release about "strategic alignment." Nobody gets acquired. Nobody wins. The real players don't play it that way — and last week, Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus, a privately held medtech out of Marietta, Georgia, and attached an exclusive option to acquire MiRus's TAVR business for up to $3 billion more. That is not tourism. That is warfare.

Let me walk you through exactly what happened here, why it matters, and what it tells you about the direction corporate venture is heading. Because if you're watching this space, this deal is a template.

What MiRus Actually Builds

MiRus is working on one thing that matters in this context: the Siegel TAVR valve. TAVR — transcatheter aortic valve replacement — is a catheter-based procedure that replaces a diseased aortic valve without open-heart surgery. It is one of the fastest-growing segments in structural heart. The global TAVR market was worth roughly $7 billion in 2024 and is projected to exceed $11 billion by 2030.

Edwards Lifesciences and Medtronic have owned this market for years. Edwards's SAPIEN platform and Medtronic's Evolut system are entrenched. Boston Scientific does not have a competitive TAVR product. That is the whole story. That is why this deal exists.

The Siegel valve is different from anything currently approved. It is built on a proprietary rhenium alloy — the first new alloy approved for use in medical device implants in 40 years. It is balloon-expandable, nickel-free, and delivered via an 8-French system, which is meaningfully smaller than competing systems. Smaller delivery profile matters clinically. Less vascular trauma, broader patient eligibility, faster recovery.

The Siegel is not yet approved by the FDA for commercial use. MiRus completed a US Early Feasibility Study and presented 30-day results at the NY Valves meeting in mid-2025. In April 2026, they started enrollment in the STAR trial — a prospective, multicenter, randomized controlled trial. You are looking at a product that is two to four years from approval, depending on trial execution and FDA timelines.

That timeline is exactly why Boston Scientific structured this the way they did. More on that in a moment.

Mammoth's Series D and What the $355M Post-Money Tells You

Before this week, the most recent public data point on MiRus's valuation was the Series D. Mammoth — a healthcare-focused venture fund — led a $70 million round that priced MiRus at $355 million post-money. That round happened before the STAR trial launched. Before any pivotal data. Before commercial readiness in any geography.

Now Boston Scientific is pricing the equity stake at an implied valuation north of $4.4 billion — that is what $1.5 billion for 34% implies on a simple arithmetic basis. That is a 12x markup from the Series D post-money, in roughly 18 to 24 months. Mammoth and the other Series D investors are sitting on paper gains that would make most biotech funds envious.

But here is the thing: that $4.4 billion implied valuation is not the ceiling. The option to acquire the TAVR business for up to $3 billion additional is layered on top of it. If Boston Scientific exercises, the total consideration for the TAVR assets alone could exceed $4.5 billion — more than 12x Mammoth's entry. Add in the fact that MiRus retains the right to additional royalty payments based on net Siegel sales after acquisition, and the actual economic value to MiRus shareholders could go higher still.

This is not a typical venture exit. This is structured like a real estate development deal with a purchase option at completion — the investor funds the construction, watches the asset appreciate, then decides whether to exercise at a pre-negotiated price.

Boston Scientific's CVC Playbook: This Is Not New Behavior

You should understand the institutional context here. Boston Scientific is not a newcomer to strategic venturing. Under Senior Vice President Charlie Attlan, the company has built a CVC apparatus that has converted portfolio stakes into outright acquisitions multiple times.

The track record is concrete. Devoro Medical — clot retrieval. Preventice Solutions — remote cardiac monitoring. Farapulse — pulsed field ablation for atrial fibrillation. Cryterion Medical — cryo-balloon ablation technology. NxThera — convective water vapor ablation for BPH. Each of these started as a venture stake. Each became an acquisition. The pattern is not accidental. It is the entire strategy.

Farapulse is the most instructive example. Boston Scientific backed Farapulse early, watched pulsed field ablation become the most disruptive technology in electrophysiology, and exercised. They bought the rest of the company. The Farapulse FARAWAVE system has since become a core commercial driver in Boston Scientific's EP segment. That segment grew double digits in Q1 2026, contributing to the company's reported $5.2 billion in net sales for the quarter — 11.6 percent year-over-year growth. The playbook works.

Jay Yadav, the founder of MiRus, has his own history with Boston Scientific. His prior company, Smart Therapeutics, was acquired by Boston Scientific directly. Before that, CardioMEMS went to St. Jude Medical; Angioguard went to Johnson & Johnson. Yadav has exited serially to strategics. This is not Boston Scientific stumbling into a deal. This is a relationship trade. They knew what they were buying before they wrote the check.

The Option Structure: Borrowed from Big Tech

Here is the most interesting part of this deal for anyone thinking about where corporate venture is heading.

Boston Scientific did not buy MiRus. They bought a 34% stake and an exclusive option on the TAVR business specifically. Not the whole company. Not the mitral valve pipeline. Not the tricuspid assets. The TAVR business — with a separate, additional option on the mitral and tricuspid assets if they want them later.

This is the acqui-hire playbook from tech applied to medtech. Last year, Nvidia entered a $20 billion licensing and talent arrangement with AI chip startup Groq. They did not acquire Groq outright. They secured a perpetual license to Groq's patent portfolio and software stack, brought on key engineering leadership, and left the remaining business operating. Full ownership without full acquisition cost. Full optionality without full commitment.

Boston Scientific is doing the same thing, adapted for the medtech regulatory environment. By taking a 34% stake in MiRus as a holding company — not just the TAVR division — they get a window into everything Yadav is building: TAVR, mitral, tricuspid, whatever comes next. They sit in the boardroom. They see the pipeline data before anyone else. And they get to decide — after watching the STAR trial results — whether to exercise the TAVR option.

This structure also sidesteps antitrust scrutiny that a full acquisition might attract while the TAVR technology is still pre-approval. Buy the whole thing now, and regulators might want a conversation. Take a minority stake with an option, and you are an investor, not a monopolist. By the time you exercise, the technology is approved, the clinical data is public, and the acquisition rationale is airtight.

The Medtech Venture Context: Why Now

This deal does not exist in a vacuum. Medtech venture had a rough few years after the 2021 highs. Back then, quarterly investment routinely exceeded $4 billion and deal counts hit 635 annually. Then rates went up, risk appetite contracted, and the exit market froze. Many medtech VCs spent 2022 through 2024 doing extension rounds and portfolio triage.

JP Morgan, using DealForma data, reported that medtech venture funding in Q1 2026 totaled $2.5 billion across 79 rounds. That is a recovery — not to 2021 levels, but a meaningful rebound. The exit environment matters for that recovery, and the MiRus deal is exactly the kind of signal that resets LP expectations about medtech exit multiples.

When Mammoth can point to a 12x markup from Series D to a Boston Scientific stake price, that is a story they can take to their LPs. That story attracts capital back into the asset class. More capital into early-stage medtech means more MiRus-type companies getting funded. More MiRus-type companies means more deals like this one. The cycle feeds itself.

The Bear Case: What Could Go Wrong

I would be doing you a disservice if I only presented the bull case. There are real risks here that you need to think through.

First: the option structure locks out competitive bidders. Boston Scientific now holds an exclusive option on the TAVR business. If the STAR trial data comes back exceptional — which is the whole point of the trial — Edwards Lifesciences cannot swoop in and offer MiRus shareholders a premium. Abbott cannot. Medtronic cannot. The exclusivity is the entire value of the option from Boston Scientific's perspective, but it eliminates the auction dynamic that typically maximizes seller value. Mammoth and MiRus shareholders accepted this trade-off for $1.5 billion in cash now. That is a defensible decision. But they gave up something real.

Second: the valuation multiple is aggressive. The $4.4 billion implied equity value prices in a product that is pre-approval, pre-pivotal data, pre-FDA, in a category where clinical trial failure is a real possibility. Balloon-expandable TAVR valves carry procedural risks. The STAR trial is randomized and controlled — the results will matter. If the Siegel shows non-inferiority problems versus existing systems, the $3 billion acquisition option becomes worthless paper. Boston Scientific's $1.5 billion stake is at risk.

Third: the rhenium alloy is novel, which is a double-edged sword. Novel material science gets you differentiation and IP moats. It also means longer regulatory scrutiny, potential for unexpected biocompatibility issues at scale, and a manufacturing ramp that is harder to predict than commoditized stainless steel or cobalt-chromium systems. First-in-kind is good for press releases. It is harder to underwrite in a clinical trial.

Fourth: Boston Scientific's balance sheet is now committed. They spent $1.5 billion in a single check on a pre-approval product. Q1 2026 revenue was $5.2 billion — that is a nearly one-quarter revenue commitment to an unproven asset. CFO Jonathan Monson is targeting full-year adjusted operating margin expansion of 50 to 75 basis points. That math gets harder if additional R&D spending flows into the MiRus relationship and STAR trial support.

What This Means for Corporate Venture In The Next 24 Months

Most CVCs are playing checkers. Small checks, passive positions, zero conviction. They exist to generate deal flow, get invited to conferences, and justify headcount in a corporate innovation budget. They do not move needles. They do not build moats.

What Boston Scientific did here is fundamentally different. This is $1.5 billion committed today for the right to own a disruptive TAVR platform tomorrow — at a pre-negotiated price that was set before pivotal trial data exists. If the Siegel works clinically, Boston Scientific exercises and acquires a product that could directly challenge Edwards Lifesciences's multi-billion-dollar SAPIEN franchise. If the Siegel fails, they lose the stake but learned everything about Yadav's next platform and kept everyone else out of the deal in the interim.

That risk-reward profile is not venture capital in the traditional sense. It is strategic option buying. You are not underwriting a company. You are buying the right to own a market position — while simultaneously eliminating the possibility that a competitor beats you to it.

This is what serious corporate venture looks like. Not a $5 million check for brand association. Not a seat observer seat on a Series B. A $1.5 billion commitment with a $3 billion option attached, made by a company with a documented track record of converting portfolio stakes into acquisitions that become commercial growth drivers.

Watch how many other large-cap medtech companies try to replicate this structure in the next 24 months. My bet is that the Boston Scientific-MiRus deal becomes the template that gets cited in every corporate development meeting at Abbott, Stryker, and Zimmer Biomet through 2028.

Most CVCs are tourism. This is warfare. Now you know the difference.

---

Jeff Barnes, MBA, writes on private equity, corporate venture, and medtech deal structure for Angel Investors Network. He has spent over a decade analyzing healthcare exits and structural heart investments.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.

This article is for informational and educational purposes only and does not constitute investment, legal, or tax advice. Always consult a qualified financial advisor, attorney, or tax professional before making investment decisions.